FI890312L - Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein. - Google Patents

Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein. Download PDF

Info

Publication number
FI890312L
FI890312L FI890312A FI890312A FI890312L FI 890312 L FI890312 L FI 890312L FI 890312 A FI890312 A FI 890312A FI 890312 A FI890312 A FI 890312A FI 890312 L FI890312 L FI 890312L
Authority
FI
Finland
Prior art keywords
tillvaext
modularande
amfiregulin
bifunctional
glycoprotein
Prior art date
Application number
FI890312A
Other languages
English (en)
Finnish (fi)
Other versions
FI890312A7 (fi
FI890312A0 (fi
Inventor
Mohammed Shoyab
Donald Vicki L Mc
James G Bradley
Greg Plowman
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/297,816 external-priority patent/US5115096A/en
Application filed by Oncogen filed Critical Oncogen
Publication of FI890312A0 publication Critical patent/FI890312A0/fi
Publication of FI890312A7 publication Critical patent/FI890312A7/fi
Publication of FI890312L publication Critical patent/FI890312L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
FI890312A 1988-01-25 1989-01-20 Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein. FI890312L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14832788A 1988-01-25 1988-01-25
US18188488A 1988-04-15 1988-04-15
US07/297,816 US5115096A (en) 1988-04-15 1989-01-17 Amphiregulin: a bifunctional growth modulating glycoprotein

Publications (3)

Publication Number Publication Date
FI890312A0 FI890312A0 (fi) 1989-01-20
FI890312A7 FI890312A7 (fi) 1989-07-26
FI890312L true FI890312L (fi) 1989-07-26

Family

ID=27386678

Family Applications (1)

Application Number Title Priority Date Filing Date
FI890312A FI890312L (fi) 1988-01-25 1989-01-20 Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.

Country Status (24)

Country Link
US (1) US5830995A (enExample)
JP (1) JPH02104596A (enExample)
CN (1) CN1038126A (enExample)
AT (1) AT399720B (enExample)
AU (1) AU623109B2 (enExample)
BE (1) BE1004201A5 (enExample)
CH (1) CH681080A5 (enExample)
DE (1) DE3902157A1 (enExample)
DK (1) DK29989A (enExample)
ES (1) ES2016432A6 (enExample)
FI (1) FI890312L (enExample)
FR (1) FR2628109B1 (enExample)
GB (1) GB2214185B (enExample)
GR (1) GR1000849B (enExample)
HU (1) HUT52545A (enExample)
IE (1) IE61146B1 (enExample)
IL (1) IL89033A (enExample)
IT (1) IT1229504B (enExample)
MY (1) MY104980A (enExample)
NL (1) NL8900178A (enExample)
NO (1) NO177788C (enExample)
NZ (1) NZ227729A (enExample)
SE (1) SE504554C2 (enExample)
YU (1) YU16989A (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262298A (en) * 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
EP0444961A1 (en) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
ATE199095T1 (de) * 1990-10-16 2001-02-15 Childrens Medical Center Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf)
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6235884B1 (en) 1993-06-15 2001-05-22 Scios Nova, Inc. Heparin binding mitogen with homology to epidermal growth factor (EGF)
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
US6204359B1 (en) * 1995-12-22 2001-03-20 Innogenetics N.V. Form of amphiregulin, methods for producing and using the same and compositions comprising the same
US6852506B1 (en) 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
US5948889A (en) * 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
EP0972021A1 (en) * 1997-04-11 2000-01-19 Human Genome Sciences, Inc. Extracellular/epidermal growth factor like protein
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
CA2433194C (en) * 2000-10-10 2012-04-03 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) * 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US20030054366A1 (en) * 2001-01-23 2003-03-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
ATE376184T1 (de) * 2001-03-09 2007-11-15 Univ Oklahoma Epitop-untersuchung mit hla
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
RU2224255C2 (ru) * 2002-04-15 2004-02-20 Государственное учреждение Нижегородский научно-исследовательский кожно-венерологический институт Способ прогнозирования течения псориаза
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
WO2004018499A2 (en) * 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
JP2006517109A (ja) * 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
DE602005023714D1 (de) 2004-02-20 2010-11-04 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
CA2568427A1 (en) * 2004-05-27 2006-01-12 Tanox, Inc. Method for preventing and treating mast cell mediated diseases
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2046350A4 (en) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc COMPOSITION AND METHOD FOR DELIVERING AMPLIFIER / CO-ACTIVATOR OF BMP-2 TO ENHANCE OSTEOGENESIS
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
DE102011056933A1 (de) * 2011-12-22 2013-06-27 Bayerische Motoren Werke Aktiengesellschaft Interieurbauteil für ein Kraftfahrzeug
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
WO2017083491A2 (en) * 2015-11-10 2017-05-18 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
CA3059593A1 (en) 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN112779209B (zh) * 2019-11-08 2023-01-24 合肥中科普瑞昇生物医药科技有限公司 原代乳腺上皮细胞培养基、培养方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein

Also Published As

Publication number Publication date
FR2628109B1 (fr) 1993-04-09
SE504554C2 (sv) 1997-03-03
AT399720B (de) 1995-07-25
JPH02104596A (ja) 1990-04-17
AU2876989A (en) 1989-08-24
CH681080A5 (enExample) 1993-01-15
CN1038126A (zh) 1989-12-20
FI890312A7 (fi) 1989-07-26
GR1000849B (el) 1993-02-17
YU16989A (en) 1991-10-31
NO177788C (no) 1995-11-22
IE61146B1 (en) 1994-10-05
NO890299L (no) 1989-07-26
GR890100037A (en) 1990-01-31
NL8900178A (nl) 1989-08-16
NO890299D0 (no) 1989-01-24
GB2214185A (en) 1989-08-31
IL89033A (en) 1994-05-30
ES2016432A6 (es) 1990-11-01
SE8900247L (sv) 1989-07-26
NO177788B (no) 1995-08-14
NZ227729A (en) 1992-02-25
DE3902157A1 (de) 1989-07-27
DK29989D0 (da) 1989-01-24
FI890312A0 (fi) 1989-01-20
IE890207L (en) 1989-07-25
SE8900247D0 (sv) 1989-01-24
BE1004201A5 (fr) 1992-10-13
FR2628109A1 (fr) 1989-09-08
AU623109B2 (en) 1992-05-07
GB2214185B (en) 1992-06-17
MY104980A (en) 1994-07-30
DK29989A (da) 1989-07-26
IT8919186A0 (it) 1989-01-25
GB8901469D0 (en) 1989-03-15
IL89033A0 (en) 1989-08-15
HUT52545A (en) 1990-07-28
US5830995A (en) 1998-11-03
ATA14789A (de) 1994-11-15
IT1229504B (it) 1991-09-03

Similar Documents

Publication Publication Date Title
FI890312L (fi) Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
FI911142A0 (fi) Ett tredimensionellt cell- och vaevnadskultiveringssystem.
FI895623A0 (fi) Detekteringsanordning foer ett biologiskt objekt.
FI906185A0 (fi) Foerpackning avsedd foer ett vaetskeartat aemne.
FI885131L (fi) Hoegtalare givande ett tredimensionellt stereoljudintryck.
FI890746L (fi) Foerfarande foer framstaellning av ett dekorativt haerdplastlaminat.
FI885210A0 (fi) Arrangemang foer undersoekning av ett objekt.
FI895825A0 (fi) Fysioterapeutisk anordning foer producering av ett magnetiskt faelt foer terapeutisk anvaendning.
FI903852A0 (fi) Foerfarande foer framstaellning av ett rekombinat subenhetsvaccin mot pseudorabiesinfektion.
FI886024L (fi) Hjulupphaengningsanordning foer ett raelsfordon.
FI894309L (fi) Avlaenkningskrets foer ett televisionsbildroer.
FI905259A0 (fi) Sammansaettning foer infoering i ett hoegtemperaturomraode.
FI904471A0 (fi) Styrbar hjulaxel foer ett motorfordon.
FI902362A0 (fi) Anordning foer att hissa ett baotsegel.
FI890651A7 (fi) Anordning foer instaellning av ett strypblad.
FI900234A0 (fi) Manoevringsanordning foer ett sprutmunstycke.
FI880665L (fi) Anordning foer formande av ett isolerskikt.
FI882657A7 (fi) Anordning foer aostadkommande av ett skyddande skikt fraon smaelta metaller.
FI891608L (fi) Gummitaetning foer ett roerfaestdon.
FI882016A0 (fi) Foerfarande foer tillverkning av ett glasfoeremaol.
FI890644L (fi) Foerfarande foer framkallning av ett fotografiskt tryckmaterial.
FI882195A0 (fi) Ett publiktelefonsystem foer anvaendning i ett resetelefonnaet.
FI882787A0 (fi) Foerfarande foer framstaellning av ett laminerat timmerelement.
FI883655A7 (fi) R.a.m.-princip.
FI884324A0 (fi) Anordning foer ett skyddsrum.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: ONCOGEN